US20220022433A1 - Method for developing organ that lacks specific functional cell - Google Patents
Method for developing organ that lacks specific functional cell Download PDFInfo
- Publication number
- US20220022433A1 US20220022433A1 US17/495,087 US202117495087A US2022022433A1 US 20220022433 A1 US20220022433 A1 US 20220022433A1 US 202117495087 A US202117495087 A US 202117495087A US 2022022433 A1 US2022022433 A1 US 2022022433A1
- Authority
- US
- United States
- Prior art keywords
- cell
- organ
- pancreas
- formation
- inhibited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 210000000056 organ Anatomy 0.000 title abstract description 114
- 210000004027 cell Anatomy 0.000 claims abstract description 135
- 210000003754 fetus Anatomy 0.000 claims abstract description 19
- 210000000130 stem cell Anatomy 0.000 claims description 23
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 18
- 230000012010 growth Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 78
- 241001465754 Metazoa Species 0.000 abstract description 31
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 28
- 210000000496 pancreas Anatomy 0.000 description 73
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 36
- 102000004877 Insulin Human genes 0.000 description 18
- 108090001061 Insulin Proteins 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 18
- 210000004923 pancreatic tissue Anatomy 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 102000038379 digestive enzymes Human genes 0.000 description 12
- 108091007734 digestive enzymes Proteins 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002459 blastocyst Anatomy 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 102000051325 Glucagon Human genes 0.000 description 6
- 108060003199 Glucagon Proteins 0.000 description 6
- 238000003169 complementation method Methods 0.000 description 6
- 229960004666 glucagon Drugs 0.000 description 6
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101150092640 HES1 gene Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 210000003890 endocrine cell Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 101150111723 PDX1 gene Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002907 exocrine cell Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 235000013384 milk substitute Nutrition 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101150047851 IL2RG gene Proteins 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- -1 biodiastase Proteins 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000029795 kidney development Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940102988 levemir Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940026454 tresiba Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
Definitions
- the present invention relates to a method for developing a secondary organ by using a non-human animal in which organ formation is inhibited.
- the present invention also relates to a non-human animal that has a secondary organ lacking a specific functional cell. Furthermore, the present invention relates to a method for producing a cell. Furthermore, the present invention relates to a secondary organ lacking a specific functional cell.
- Blastocyst complementation method is a method for forming an organ derived from cells of a normal animal by injecting the cells of the normal animal into a blastocyst of an animal lacking an organ. Utilizing this blastocyst complementation method, the present inventors have successfully generated a chimeric pig that had a pancreas derived from a donor by injecting an embryo from a normal pig (donor embryo) into an embryo from a pig lacking a pancreas (host embryo) and allowing the host embryo to develop in the body of a surrogate parental pig (Non Patent Literature 1).
- a pig that has a human pancreas is expected to be generated by using a human pluripotent stem cell as a donor and such a human pancreas may be used for islet transplantation.
- a human organ for example, a pancreas
- a functional cell for example, a ⁇ cell
- organ or tissue suitable for cell growth to perform such cell transplantation wherein the organ or the tissue lacks only the specific functional cell (for example, a ⁇ cell) and serves as an environment for producing and growing the above described specific functional cell.
- specific functional cell for example, a ⁇ cell
- a newborn piglet in which pancreas formation is inhibited dies about three days after birth due to hyperglycemia and dyspepsia.
- the present inventors raised such a newborn by administering insulin and a digestive enzyme combination thereto so that the newborn survived, and have found that as the newborn grew, pancreas-like tissue formed in a space where a pancreas would have formed under normal circumstances.
- the present inventors also have found that this pancreas-like tissue came to produce a digestive enzyme and glucagon but did not come to produce insulin (in other words, no ⁇ cell formed).
- pancreas-like tissue that had not been found during the fetal stage started to develop by the above described raising and further formed into an incomplete pancreas in which no insulin-producing ⁇ cell formed while other endocrine cells and/or an exocrine cell existed. It was also totally unexpected that only insulin was not produced although the digestive enzyme and glucagon were produced.
- the ⁇ cell-lacking pancreas-like tissue formed by the above described raising has an environment (such as a tissue structure and function) other than the ⁇ cell and is believed to be an excellent “vacant niche” for growing a progenitor cell of the ⁇ cell and a pluripotent stem cell. Therefore, it is believed that a human ⁇ cell can be produced efficiently by transplanting, for example, a progenitor cell of a ⁇ cell derived from a human into the ⁇ cell-lacking pancreas-like tissue.
- the present invention provides the following [1] to [18].
- the present invention provides the method for developing a secondary organ by using a non-human animal in which organ formation is inhibited, the non-human animal that has a secondary organ lacking a specific functional cell, the method for producing a cell, and the secondary organ lacking a specific functional cell.
- FIG. 1 shows a photograph of internal organs of a pig in which pancreas formation is inhibited (right) and a wild type pig (left).
- FIG. 2 shows a graph showing change over time in the weight (top) and the blood glucose level (bottom) of the pig in which pancreas formation is inhibited and the wild type pig.
- FIG. 3 shows a table showing blood biochemical parameters of the pig in which pancreas formation is inhibited and the wild type pig (23 days old and 60 days old).
- FIG. 4 shows a photograph showing the result of immunostaining of the pancreatic tissue of the pig in which pancreas formation is inhibited (right) and the wild type pig (left) (38 days old).
- the pancreas of the pig in which pancreas formation is inhibited has a pancreatic islet-like structure including a glucagon-producing cell but production of insulin was not observed.
- FIG. 5 shows a photograph of a secondary pancreas of the pig in which pancreas formation is inhibited (right) developed by supported raising (raising supported by administration of insulin and a digestive enzyme), and the pancreas of the wild type pig (left). It has an enough capacity for injecting cells from the outside.
- FIG. 6 shows a photograph showing HE staining of the pancreatic tissue of the pig in which pancreas formation is inhibited developed by supported raising (lower row) and the pancreatic tissue of the wild type pig (upper row).
- the lobule of the pig in which pancreas formation is inhibited was smaller than the lobule of the wild type pig, but included tissues other than ⁇ cells.
- FIG. 7 shows a table showing the body weight, the pancreas weight, and the ratio of pancreas weight to body weight of the pig in which pancreas formation is inhibited (upper row) and the wild type pig (lower row).
- FIG. 8 shows a photograph showing the result of immunostaining for amylase of the pancreatic tissue of the pig in which pancreas formation is inhibited (right) and the wild type pig (left). An amylase-positive cell was observed in the pancreatic tissue of the pig in which pancreas formation is inhibited.
- FIG. 9 shows a photograph of the pancreatic tissue of the pig in which pancreas formation is inhibited implanted with a fibroblast.
- the left photograph is an HE staining image and the right photograph is a fluorescent image.
- the transplanted fibroblast is stained with CM-DiI.
- FIG. 10 shows an immunohistochemical staining image of the retina of the pig in which pancreas formation is inhibited (right) and the wild type pig (left).
- a neovessel has developed due to diabetic retinopathy.
- FIG. 11 shows a photograph of the right eye of the pig in which pancreas formation is inhibited (right) and the wild type pig (left).
- the pig in which pancreas formation is inhibited has developed a cataract characteristic of diabetes.
- the method of the present invention for developing a secondary organ by using a non-human animal in which organ formation is inhibited includes the step of (1) raising a newborn or a fetus of the non-human animal in which organ formation is inhibited by complementing at least a part of the function of the organ whose formation is inhibited.
- Examples of the organ whose formation is to be inhibited may include a pancreas, and the organ may be any organ other than the pancreas as long as the newborn or the fetus can survive even if formation of the organ is inhibited.
- Examples of the organ other than the pancreas may include a kidney.
- Inhibition of organ formation can be performed by genetic modification that modifies a gene of the non-human animal having the organ.
- inhibition of pancreas formation can be performed by using a Pdx1-Hes1 gene composed of a Hes1 gene linked to a Pdx1 gene promoter, specifically by overexpressing the Hes1 gene under the control of the Pdx1 promoter (Matsunari et al., PNAS 110: 4557-4562 (2013)).
- Organ formation may also be inhibited by administration of an agent.
- the effect of the present invention cannot be achieved when organ formation is disabled by destroying the Pdx1 gene.
- Inhibition of kidney formation can be performed, for example, by overexpressing a Six2-Notch2 gene (Fujimura et al., J Am Soc Nephrol, 21:803-810, 2010) and by inhibiting or suppressing expression of a gene that controls kidney development, such as Sall1 and Pax2.
- a Six2-Notch2 gene Fujimura et al., J Am Soc Nephrol, 21:803-810, 2010
- a gene that controls kidney development such as Sall1 and Pax2.
- the animal to be subjected to inhibition of organ formation may be any animal as long as the animal is not a human, but is preferably a mammal.
- Specific examples of the animal may include a mouse, a rat, a hamster, a guinea pig, a rabbit, a dog, a cat, a horse, a cow, a sheep, a pig, a goat, and a monkey.
- a pig can be a preferable animal.
- a “secondary organ” means an organ-like tissue that was formed in a site within the body of a non-human animal by raising and growing the animal, wherein the site is a site where a formation-inhibited organ (for example, a pancreas) would have formed under normal circumstances.
- the secondary organ may have 100% or a part of the function of the normal organ.
- Examples of a preferable secondary organ may include a secondary organ lacking a specific functional cell.
- a “functional cell” means a cell that is included in an organ and has some function, such as an a cell, a ⁇ cell, and a ⁇ cell in the pancreas. Examples of a preferable functional cell may include a ⁇ cell.
- Examples of a preferable organ lacking a specific functional cell may include a pancreas lacking a ⁇ cell.
- a newborn or a fetus of the non-human animal in which organ formation is inhibited can be obtained by a known method.
- a newborn or a fetus of a pig whose pancreas formation is inhibited by using the Pdx1-Hes1 gene can be obtained by the following methods (a) to (d).
- “Complementing at least a part of the function of the organ whose formation is inhibited” means administering an enzyme or a hormone that the organ would produce under normal circumstances or an agent having a function equivalent thereto; transplanting, for example, a cell that substitutes for the function of the organ; using a device that substitutes for the function of the organ; or the like.
- the function of the organ does not need to be fully complemented and may be partially complemented as long as the newborn or the fetus of the non-human animal can survive.
- a specific complementation method can be decided as appropriate depending on the organ type. For example, for complementing the function of the pancreas, all or some of the hormones and digestive enzymes produced by the pancreas may be administered.
- the pancreas produces hormones such as glucagon, insulin, and somatostatin, all or some of which can be administered.
- the pancreas also produces digestive enzymes such as a proteolytic enzyme (chymotrypsin and trypsin), a polysaccharide-degrading enzyme (amylase), and a lipolytic enzyme (lipase), all or some of which can be administered.
- digestive enzymes such as a proteolytic enzyme (chymotrypsin and trypsin), a polysaccharide-degrading enzyme (amylase), and a lipolytic enzyme (lipase), all or some of which can be administered.
- an agent having a function equivalent thereto may be administered instead of administering the actual hormones and/or digestive enzymes produced by the pancreas.
- an agent having a function equivalent thereto may be administered.
- Examples of a preferable raising method for complementing the function of the pancreas may include a raising method that includes administering insulin and
- Raising the newborn or the fetus can be performed in accordance with an ordinary method except that at least a part of the function of the formation-inhibited organ is complemented.
- human-derived cells are transplanted into the secondary organ formed by the above described method, and such heterotransplantation causes rejection.
- SCID immunodeficiency
- Methods for inducing such immunodeficiency are reported in many publications, and the present inventors have generated an immunodeficient pig by knocking out an IL2RG gene (Watanabe et al., PLoS One 8(10): e76478 (2013)).
- induction of immunodeficiency can be performed according to description of such publications.
- It is also possible to induce immunological tolerance to a human-derived cell by transplanting a large quantity of human-derived cells into a fetus before immune system is established. Therefore, such a method may be used to avoid rejection caused by heterotransplantation.
- the length of the raising period for developing the secondary organ is not particularly limited.
- the developed secondary organ is intended to be used for a method described below for producing a functional cell, raising is continued until the functional cell is ready to be collected.
- the non-human animal of the present invention is a non-human animal obtained by raising a newborn or a fetus of a non-human animal in which organ formation is inhibited, wherein the non-human animal has a secondary organ lacking a specific functional cell.
- the non-human animal of the present invention can be used for the method described below for producing a functional cell, and furthermore can also be used as a model animal for a disease or a malformation.
- the specific functional cell that the non-human animal lacks is a ⁇ cell, which contributes to insulin production
- the non-human animal can be used as a model animal for a complication caused by diabetes, such as retinopathy, nephropathy, neuropathy, angiopathy, and cataract.
- the type of the functional cell, the type of the secondary organ lacking a specific functional cell, and the type of the animal to be subjected to inhibition of organ formation may be similar to those described in the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.”
- the method for inhibiting organ formation and the method for raising a newborn or a fetus can also be performed in a similar manner to the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.”
- a “non-human animal,” which is a “product,” is specified not by the structure or characteristic thereof but by a method for producing the same.
- the reason for this is that the “non-human animal” is an organism and thus has an extremely complicated structure and characteristic, and therefore carrying out work for specifying the structure and characteristic thereof requires remarkably excessive economic expense and time.
- the inventive method for producing a functional cell includes the steps of (1) transplanting at least a progenitor cell of the functional cell or a pluripotent stem cell into the secondary organ of the non-human animal; and (2) inducing the progenitor cell or the pluripotent stem cell to the functional cell.
- a “progenitor cell of a functional cell” means a cell that originates from a stem cell and can differentiate into a functional cell, and examples thereof include a progenitor cell of an ⁇ cell, a progenitor cell of a ⁇ cell, and a progenitor cell of a ⁇ cell in the pancreas.
- Examples of a preferable progenitor cell of a functional cell may include the progenitor cell of a ⁇ cell.
- a pluripotent stem cell whose differentiation was appropriately induced may be transplanted.
- An embryonic stem cell (ES cell), an induced pluripotent stem cell (iPS cell), or the like can be used as the pluripotent stem cell.
- a cell associated with pancreatic islet formation is preferably transplanted.
- the cell associated with pancreatic islet formation may include an interstitial cell, a cell involved in induction of a blood vessel, and an endocrine cell.
- the main purpose of the inventive method for producing a functional cell is producing a functional cell for transplantation into a human, and therefore, the progenitor cell or pluripotent stem cell to be transplanted is preferably derived from a human.
- the number of cells to be transplanted into the secondary organ can be decided as appropriate depending on the type of the animal, the cell type, the type of the secondary organ, and the like. For example, when the cells are transplanted into the pancreas of a pig, the number of cells is usually, without particular limitations, 1 ⁇ 10 6 to 5 ⁇ 10 8 .
- the timing for performing transplantation can be decided as appropriate depending on the cell type, the type of the secondary organ, the type of the animal, and the like.
- transplantation is usually performed, without particular limitations, at the timing when the pig is 10 to 90 days old.
- the cells to be transplanted are human-derived cells
- heterotransplantation causes rejection.
- the non-human animal into which cells are transplanted is the immunodeficient animal or the animal with induced immunological tolerance to human-derived cells as described above, rejection can be avoided. Otherwise, it is preferable to avoid rejection by administering an immunosuppressive agent (for example, ciclosporin) to the non-human animal.
- an immunosuppressive agent for example, ciclosporin
- the secondary organ lacking a specific functional cell lacks the specific functional cell
- the secondary organ has other functional cells and tissues, and thus, the secondary organ is presumed to have an environment favorable for differentiation into the specific functional cell. Therefore, when progenitor cells or pluripotent stem cells are transplanted into this organ, the cells are expected to differentiate into the specific functional cells without requiring a particular treatment.
- a substance such as an agent and a growth factor may be injected into the secondary organ to promote differentiation into the specific functional cell.
- the functional cells are collected from the secondary organ at an appropriate time after transplantation.
- the timing for collection can be decided as appropriate depending on the cell type, the type of the secondary organ, the type of the animal, and the like.
- the ⁇ cells are usually collected, without particular limitations, 1 to 12 months after transplantation.
- a method other than the method of the present invention for example, a blastocyst complementation method can be used to produce a human-derived functional cell in a non-human animal
- the inventive method is superior to a conventional method in the following respects.
- human-derived cells are transplanted at an early stage of development such as a blastocyst stage. Such transplantation at an early stage of development leads to dilution of the human-derived cells. Specifically, some of the transplanted human-derived cells differentiate into functional cells but the majorities thereof differentiate into different cells other than the functional cells or disappear, which leads to a lower quantity of resulting human-derived functional cells. In contrast to this method, in the method of the present invention, human-derived cells are transplanted into an already differentiated organ. Therefore, it is expected that the majority of the transplanted cells differentiate into functional cells and abundant human-derived functional cells are obtained.
- human-derived cells are transplanted into the blastocyst.
- the cells included in the blastocyst are undifferentiated cells and these cells differentiate into adult cells over time.
- the transplanted human-derived cells cannot become functional cells in the end unless the transplanted cells themselves differentiate at the same pace as the differentiation progress of such host cells. Therefore, it is presumed that there are many human-derived cells that cannot become functional cells because of relation to the differentiation progress of the host cells.
- human-derived cells are transplanted into an already differentiated organ, and therefore, the above described problem associated with the differentiation progress of the host cells is presumed not to occur.
- the secondary organ of the present invention is a secondary organ developed by raising a newborn or a fetus of a non-human animal in which organ formation is inhibited, wherein the secondary organ lacks a specific functional cell.
- the type of the functional cell, the type of the secondary organ lacking a specific functional cell, and the type of the animal to be subjected to inhibition of organ formation may be similar to those described in the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.”
- the method for inhibiting organ formation and the method for raising a newborn or a fetus can also be performed in a similar manner to the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.”
- the present inventors previously generated a chimeric pig that had a pancreas derived from a donor by injecting an embryo from a normal pig (donor embryo) into an embryo from a Pdx1-Hes1 gene-carrying and pig in which pancreas formation is inhibited (host embryo) and then allowing this to develop in the body of a surrogate parental pig (Matsunari et al., PNAS 110: 4557-4562 (2013)).
- a male of this chimeric pig can be naturally mated with a female wild type pig, thereby obtaining pancreas formation-inhibited newborns always at a certain ratio.
- Example was obtained by natural mating with such a chimeric pig.
- a newborn piglet in which pancreas formation is inhibited (precisely, that has only rudimentary pancreatic tissue) by carrying a Pdx1-Hes1 gene lacks an endocrine cell (for example, a ⁇ cell producing insulin) and an exocrine cell. Consequently, the piglet dies about three days after birth due to extreme hyperglycemia and dyspepsia.
- Insulin and a digestive enzyme combination were administered as appropriate to such a newborn piglet in which pancreas formation is inhibited to bring the blood glucose level close to a normal level and induce individual growth and development of the pancreas.
- Levemir Novo Nordisk
- Tresiba Novo Nordisk
- Insulin was administered by subcutaneous injection or continuously administered with an insulin pump.
- Berizym A daily dose of 150 mg to 750 mg of Berizym (SHIONOGI & CO., LTD.) was mixed with a milk substitute or solid (powdered) laboratory chow and given to the piglet.
- Berizym contains lipase, cellulase, biodiastase, and pancreatin.
- the piglet was fed with the milk substitute by a human or fed with milk by the mother pig. From 8 days after birth onward, the piglet was subjected to restricted feeding (the piglet is not allowed to eat ad libitum and is fed with a fixed daily amount of food) using a powdered milk substitute or powdered laboratory chow.
- FIG. 3 Blood biochemical parameters for the pig in which pancreas formation is inhibited ( FIG. 3 ) indicate that insulin production remained abolished and glucagon production occured as the pig grew. Glucagon production was also confirmed by immunostaining of the developed pancreatic tissue ( FIG. 4 ). In contrast, no insulin production was observed by immunostaining of the pancreatic tissue, either ( FIG. 4 ).
- pancreatic tissue Supported raising of the newborn piglet in which pancreas formation is inhibited led to development of the rudimentary pancreatic tissue ( FIGS. 5 and 6 ). Although the pancreatic tissue was about one tenth as big as a wild type pancreatic tissue ( FIG. 7 ), amylase production was also observed ( FIG. 8 ).
- pancreatic tissue developed by supported raising of the newborn piglet in which pancreas formation is inhibited lacks a ⁇ cell, which is a specific functional cell, but has other functional cells and tissue. Therefore, it is presumed that transplanting into this tissue a progenitor cell of the specific functional cell or a pluripotent stem cell whose differentiation was appropriately induced allows for establishment and growth of the specific functional cell.
- autologous cells fibroblasts
- pancreatic tissue of a 3.5-month-old pig in which pancreas formation is inhibited. Consequently, the autologous cells formed a colony ( FIG. 9 ).
- the cell to be transplanted is a progenitor cell of a ⁇ cell or a pluripotent stem cell
- ⁇ cells can be formed and grown by utilizing the environment of the pancreatic tissue.
- human pancreatic functional cells for example, ⁇ cells
- human pluripotent stem cells can be developed by allowing human pluripotent stem cells to establish themselves in the environment within the developing pancreatic tissue of the pig in which pancreas formation is inhibited.
- a newborn piglet in which pancreas formation is inhibited was raised according to the method described in Example 2.
- the immunohistochemically stained image of the retina was observed after 80 days of raising and a pathological image characteristic of diabetic retinopathy was identified ( FIG. 10 ).
- the retina of a wild type pig was healthy after raising for the same length of time ( FIG. 10 ).
- a newborn piglet in which pancreas formation is inhibited was raised according to the method described in Example 2.
- the eye was observed after 39 days of raising and development of cataract was identified ( FIG. 11 ).
- the eye of a wild type pig was healthy after raising for the same length of time ( FIG. 11 ).
- the present invention relates to a non-human animal that has a secondary organ lacking a specific functional cell, and thus, is applicable to the field of industry that handles such an animal.
Abstract
Provided is a method for developing a secondary organ by using a non-human animal in which organ formation is inhibited, for the purpose of establishing a process for producing a functional cell such as a β cell within the body of an animal such as a pig, the method including the step of raising a newborn or a fetus of the non-human animal in which organ formation is inhibited by complementing at least a part of the function of the organ whose formation is inhibited.
Description
- This application is a Continuation of copending application Ser. No. 16/638,440, filed on Feb. 11, 2020, which is the National Phase under 35 U.S.C. § 371 of International Application No. PCT/JP2018/034390, filed on Sep. 18, 2018, which claims the benefit under 35 U.S.C. § 119(a) to Patent Application No. 2017-178552, filed in Japan on Sep. 19, 2017, all of which are hereby expressly incorporated by reference into the present application.
- The present invention relates to a method for developing a secondary organ by using a non-human animal in which organ formation is inhibited. The present invention also relates to a non-human animal that has a secondary organ lacking a specific functional cell. Furthermore, the present invention relates to a method for producing a cell. Furthermore, the present invention relates to a secondary organ lacking a specific functional cell.
- Blastocyst complementation method is a method for forming an organ derived from cells of a normal animal by injecting the cells of the normal animal into a blastocyst of an animal lacking an organ. Utilizing this blastocyst complementation method, the present inventors have successfully generated a chimeric pig that had a pancreas derived from a donor by injecting an embryo from a normal pig (donor embryo) into an embryo from a pig lacking a pancreas (host embryo) and allowing the host embryo to develop in the body of a surrogate parental pig (Non Patent Literature 1). Although the chimera was generated between pigs in
Non Patent Literature 1, a pig that has a human pancreas is expected to be generated by using a human pluripotent stem cell as a donor and such a human pancreas may be used for islet transplantation. -
- Non Patent Literature 1: Matsunari et al., PNAS 110: 4557-4562 (2013)
- If a human organ (for example, a pancreas) or a functional cell (for example, a β cell) can be successfully produced within the body of an animal such as a pig, the problem of donor shortage in transplantation therapy can be solved.
- On the other hand, under the existing circumstances, there are many ethical problems to be solved in transplantation in which a chimeric state between a human and an animal is induced at an early stage of development and an organ or functional cell thus produced is transplanted into a human. In comparison with this, it is believed that there is a lower ethical barrier to performing cell transplantation in which a chimeric state between a human and an animal is not induced at an early stage of development, a specific functional cell (for example, a β cell) that can establish itself in a human is grown in an organ of an animal such as a pig, and the functional cell is transplanted into a human.
- However, until now, there has been no known organ or tissue suitable for cell growth to perform such cell transplantation, wherein the organ or the tissue lacks only the specific functional cell (for example, a β cell) and serves as an environment for producing and growing the above described specific functional cell.
- Under such circumstances, it is an object of the present invention to provide means for producing a functional cell within an animal body.
- A newborn piglet in which pancreas formation is inhibited dies about three days after birth due to hyperglycemia and dyspepsia. The present inventors raised such a newborn by administering insulin and a digestive enzyme combination thereto so that the newborn survived, and have found that as the newborn grew, pancreas-like tissue formed in a space where a pancreas would have formed under normal circumstances. The present inventors also have found that this pancreas-like tissue came to produce a digestive enzyme and glucagon but did not come to produce insulin (in other words, no β cell formed). It was totally unexpected that this pancreas-like tissue that had not been found during the fetal stage started to develop by the above described raising and further formed into an incomplete pancreas in which no insulin-producing β cell formed while other endocrine cells and/or an exocrine cell existed. It was also totally unexpected that only insulin was not produced although the digestive enzyme and glucagon were produced.
- The β cell-lacking pancreas-like tissue formed by the above described raising has an environment (such as a tissue structure and function) other than the β cell and is believed to be an excellent “vacant niche” for growing a progenitor cell of the β cell and a pluripotent stem cell. Therefore, it is believed that a human β cell can be produced efficiently by transplanting, for example, a progenitor cell of a β cell derived from a human into the β cell-lacking pancreas-like tissue.
- The present invention has been accomplished on the basis of the above described findings.
- Specifically, the present invention provides the following [1] to [18].
- [1] A method for developing a secondary organ by using a non-human animal in which organ formation is inhibited, including the step of:
- (1) raising a newborn or a fetus of the non-human animal in which organ formation is inhibited by complementing at least a part of the function of the organ whose formation is inhibited.
- [2] The method according to [1], wherein the secondary organ develops in such a manner that at least a part of the function complemented by the raising is impaired.
- [3] The method according to [1] or [2], wherein the secondary organ is an organ lacking a specific functional cell.
- [4] The method according to [3], wherein the functional cell is a β cell.
- [5] The method according to any of [1] to [4], wherein organ formation is inhibited by genetic modification of the non-human animal in step (1).
- [6] The method according to any of [1] to [5], wherein the organ whose formation is inhibited is a pancreas and complementation of the function of the pancreas whose formation is inhibited is performed by administering at least insulin and a digestive enzyme.
- [7] The method according to [5], wherein the genetic modification is overexpressing a Hes1 gene under the control of a Pdx1 promoter in the non-human animal.
- [8] The method according to any of [1] to [7], wherein the non-human animal is a pig.
- [9] A non-human animal obtained by raising a newborn or a fetus of a non-human animal in which organ formation is inhibited, wherein the non-human animal has a secondary organ lacking a specific functional cell.
- [10] The non-human animal according to [9], wherein the organ is a pancreas and the functional cell is a β cell.
- [11] The non-human animal according to [10], wherein the newborn or the fetus of the non-human animal is that in which organ formation is inhibited by overexpressing a Hes1 gene under the control of a Pdx1 promoter.
- [12] The non-human animal according to any of [9] to [11], wherein the non-human animal is a pig.
- [13] A secondary organ developed by raising a newborn or a fetus of a non-human animal in which organ formation is inhibited, wherein the secondary organ lacks a specific functional cell.
- [14] The secondary organ according to [13], wherein the organ is a pancreas and the functional cell is a β cell.
- [15] The secondary organ according to [14], wherein the newborn or the fetus of the non-human animal is that in which organ formation is inhibited by overexpressing a Hes1 gene under the control of a Pdx1 promoter.
- [16] The secondary organ according to any of [13] to [15], wherein the non-human animal is a pig.
- [17] The secondary organ according to any of [13] to [16], wherein a transplanted cell established itself in the secondary organ.
- [18] A method for producing a cell within the body of a non-human animal, including the step of raising the non-human animal according to [1] or [2].
- This specification encompasses the content described in the specification and/or drawing of Japanese Patent Application No. 2017-178552, which forms the basis of priority of this application.
- The present invention provides the method for developing a secondary organ by using a non-human animal in which organ formation is inhibited, the non-human animal that has a secondary organ lacking a specific functional cell, the method for producing a cell, and the secondary organ lacking a specific functional cell.
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
-
FIG. 1 shows a photograph of internal organs of a pig in which pancreas formation is inhibited (right) and a wild type pig (left). -
FIG. 2 shows a graph showing change over time in the weight (top) and the blood glucose level (bottom) of the pig in which pancreas formation is inhibited and the wild type pig. -
FIG. 3 shows a table showing blood biochemical parameters of the pig in which pancreas formation is inhibited and the wild type pig (23 days old and 60 days old). -
FIG. 4 shows a photograph showing the result of immunostaining of the pancreatic tissue of the pig in which pancreas formation is inhibited (right) and the wild type pig (left) (38 days old). The pancreas of the pig in which pancreas formation is inhibited has a pancreatic islet-like structure including a glucagon-producing cell but production of insulin was not observed. -
FIG. 5 shows a photograph of a secondary pancreas of the pig in which pancreas formation is inhibited (right) developed by supported raising (raising supported by administration of insulin and a digestive enzyme), and the pancreas of the wild type pig (left). It has an enough capacity for injecting cells from the outside. -
FIG. 6 shows a photograph showing HE staining of the pancreatic tissue of the pig in which pancreas formation is inhibited developed by supported raising (lower row) and the pancreatic tissue of the wild type pig (upper row). The lobule of the pig in which pancreas formation is inhibited was smaller than the lobule of the wild type pig, but included tissues other than β cells. -
FIG. 7 shows a table showing the body weight, the pancreas weight, and the ratio of pancreas weight to body weight of the pig in which pancreas formation is inhibited (upper row) and the wild type pig (lower row). -
FIG. 8 shows a photograph showing the result of immunostaining for amylase of the pancreatic tissue of the pig in which pancreas formation is inhibited (right) and the wild type pig (left). An amylase-positive cell was observed in the pancreatic tissue of the pig in which pancreas formation is inhibited. -
FIG. 9 shows a photograph of the pancreatic tissue of the pig in which pancreas formation is inhibited implanted with a fibroblast. The left photograph is an HE staining image and the right photograph is a fluorescent image. The transplanted fibroblast is stained with CM-DiI. -
FIG. 10 shows an immunohistochemical staining image of the retina of the pig in which pancreas formation is inhibited (right) and the wild type pig (left). In the retina of the pig in which pancreas formation is inhibited, a neovessel has developed due to diabetic retinopathy. -
FIG. 11 shows a photograph of the right eye of the pig in which pancreas formation is inhibited (right) and the wild type pig (left). The pig in which pancreas formation is inhibited has developed a cataract characteristic of diabetes. - Hereinafter, the present invention is described in detail.
- (A) Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited
- The method of the present invention for developing a secondary organ by using a non-human animal in which organ formation is inhibited includes the step of (1) raising a newborn or a fetus of the non-human animal in which organ formation is inhibited by complementing at least a part of the function of the organ whose formation is inhibited.
- Examples of the organ whose formation is to be inhibited may include a pancreas, and the organ may be any organ other than the pancreas as long as the newborn or the fetus can survive even if formation of the organ is inhibited. Examples of the organ other than the pancreas may include a kidney.
- Inhibition of organ formation can be performed by genetic modification that modifies a gene of the non-human animal having the organ. For example, inhibition of pancreas formation can be performed by using a Pdx1-Hes1 gene composed of a Hes1 gene linked to a Pdx1 gene promoter, specifically by overexpressing the Hes1 gene under the control of the Pdx1 promoter (Matsunari et al., PNAS 110: 4557-4562 (2013)). Organ formation may also be inhibited by administration of an agent. On the other hand, the effect of the present invention cannot be achieved when organ formation is disabled by destroying the Pdx1 gene. Inhibition of kidney formation can be performed, for example, by overexpressing a Six2-Notch2 gene (Fujimura et al., J Am Soc Nephrol, 21:803-810, 2010) and by inhibiting or suppressing expression of a gene that controls kidney development, such as Sall1 and Pax2.
- The animal to be subjected to inhibition of organ formation may be any animal as long as the animal is not a human, but is preferably a mammal. Specific examples of the animal may include a mouse, a rat, a hamster, a guinea pig, a rabbit, a dog, a cat, a horse, a cow, a sheep, a pig, a goat, and a monkey. Among these, a pig can be a preferable animal.
- In the present invention, a “secondary organ” means an organ-like tissue that was formed in a site within the body of a non-human animal by raising and growing the animal, wherein the site is a site where a formation-inhibited organ (for example, a pancreas) would have formed under normal circumstances. The secondary organ may have 100% or a part of the function of the normal organ. Examples of a preferable secondary organ may include a secondary organ lacking a specific functional cell. In this context, a “functional cell” means a cell that is included in an organ and has some function, such as an a cell, a β cell, and a γ cell in the pancreas. Examples of a preferable functional cell may include a β cell. Examples of a preferable organ lacking a specific functional cell may include a pancreas lacking a β cell.
- A newborn or a fetus of the non-human animal in which organ formation is inhibited can be obtained by a known method. For example, a newborn or a fetus of a pig whose pancreas formation is inhibited by using the Pdx1-Hes1 gene can be obtained by the following methods (a) to (d).
-
- (a) Artificial insemination is performed on a wild type female by using a sperm into which the Pdx1-Hes1 gene has been integrated.
- (b) In vitro fertilization is performed on an egg derived from a wild type female by using a sperm into which the Pdx1-Hes1 gene has been integrated.
- (c) A male that produces a sperm into which the Pdx1-Hes1 gene has been integrated is mated with a wild type female.
- (d) A cloned pig is generated by nuclear transplantation using a somatic cell into which the Pdx1-Hes1 gene has been integrated.
- “Complementing at least a part of the function of the organ whose formation is inhibited” means administering an enzyme or a hormone that the organ would produce under normal circumstances or an agent having a function equivalent thereto; transplanting, for example, a cell that substitutes for the function of the organ; using a device that substitutes for the function of the organ; or the like. The function of the organ does not need to be fully complemented and may be partially complemented as long as the newborn or the fetus of the non-human animal can survive. A specific complementation method can be decided as appropriate depending on the organ type. For example, for complementing the function of the pancreas, all or some of the hormones and digestive enzymes produced by the pancreas may be administered. Specifically, the pancreas produces hormones such as glucagon, insulin, and somatostatin, all or some of which can be administered. The pancreas also produces digestive enzymes such as a proteolytic enzyme (chymotrypsin and trypsin), a polysaccharide-degrading enzyme (amylase), and a lipolytic enzyme (lipase), all or some of which can be administered. Furthermore, instead of administering the actual hormones and/or digestive enzymes produced by the pancreas, an agent having a function equivalent thereto may be administered. Examples of a preferable raising method for complementing the function of the pancreas may include a raising method that includes administering insulin and the digestive enzyme. Examples of the digestive enzyme to be administered in this context may include a proteolytic enzyme, a polysaccharide-degrading enzyme, and a lipolytic enzyme.
- Raising the newborn or the fetus can be performed in accordance with an ordinary method except that at least a part of the function of the formation-inhibited organ is complemented.
- As described below, in some cases, human-derived cells are transplanted into the secondary organ formed by the above described method, and such heterotransplantation causes rejection. To avoid this rejection, it is preferable to modify a gene of the non-human animal where the secondary organ is developed, thereby inducing immunodeficiency (SCID). Methods for inducing such immunodeficiency are reported in many publications, and the present inventors have generated an immunodeficient pig by knocking out an IL2RG gene (Watanabe et al., PLoS One 8(10): e76478 (2013)). Thus, induction of immunodeficiency can be performed according to description of such publications. It is also possible to induce immunological tolerance to a human-derived cell by transplanting a large quantity of human-derived cells into a fetus before immune system is established. Therefore, such a method may be used to avoid rejection caused by heterotransplantation.
- The length of the raising period for developing the secondary organ is not particularly limited. When the developed secondary organ is intended to be used for a method described below for producing a functional cell, raising is continued until the functional cell is ready to be collected.
- (B) Non-Human Animal
- The non-human animal of the present invention is a non-human animal obtained by raising a newborn or a fetus of a non-human animal in which organ formation is inhibited, wherein the non-human animal has a secondary organ lacking a specific functional cell.
- The non-human animal of the present invention can be used for the method described below for producing a functional cell, and furthermore can also be used as a model animal for a disease or a malformation. For example, when the specific functional cell that the non-human animal lacks is a β cell, which contributes to insulin production, the non-human animal can be used as a model animal for a complication caused by diabetes, such as retinopathy, nephropathy, neuropathy, angiopathy, and cataract.
- The type of the functional cell, the type of the secondary organ lacking a specific functional cell, and the type of the animal to be subjected to inhibition of organ formation may be similar to those described in the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.” The method for inhibiting organ formation and the method for raising a newborn or a fetus can also be performed in a similar manner to the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.”
- As described above, in this specification, a “non-human animal,” which is a “product,” is specified not by the structure or characteristic thereof but by a method for producing the same. The reason for this is that the “non-human animal” is an organism and thus has an extremely complicated structure and characteristic, and therefore carrying out work for specifying the structure and characteristic thereof requires remarkably excessive economic expense and time.
- (C) Method for Producing Functional Cell
- The inventive method for producing a functional cell includes the steps of (1) transplanting at least a progenitor cell of the functional cell or a pluripotent stem cell into the secondary organ of the non-human animal; and (2) inducing the progenitor cell or the pluripotent stem cell to the functional cell.
- A “progenitor cell of a functional cell” means a cell that originates from a stem cell and can differentiate into a functional cell, and examples thereof include a progenitor cell of an α cell, a progenitor cell of a β cell, and a progenitor cell of a γ cell in the pancreas. Examples of a preferable progenitor cell of a functional cell may include the progenitor cell of a β cell. Instead of the progenitor cell of a functional cell, a pluripotent stem cell whose differentiation was appropriately induced may be transplanted. An embryonic stem cell (ES cell), an induced pluripotent stem cell (iPS cell), or the like can be used as the pluripotent stem cell. Other cells may also be transplanted in addition to the progenitor cell of a functional cell and the pluripotent stem cell. For example, in the case of the pancreas, a cell associated with pancreatic islet formation is preferably transplanted. Examples of the cell associated with pancreatic islet formation may include an interstitial cell, a cell involved in induction of a blood vessel, and an endocrine cell.
- The main purpose of the inventive method for producing a functional cell is producing a functional cell for transplantation into a human, and therefore, the progenitor cell or pluripotent stem cell to be transplanted is preferably derived from a human.
- The number of cells to be transplanted into the secondary organ can be decided as appropriate depending on the type of the animal, the cell type, the type of the secondary organ, and the like. For example, when the cells are transplanted into the pancreas of a pig, the number of cells is usually, without particular limitations, 1×106 to 5×108.
- The timing for performing transplantation can be decided as appropriate depending on the cell type, the type of the secondary organ, the type of the animal, and the like. When the cells are transplanted into the pancreas of a pig, transplantation is usually performed, without particular limitations, at the timing when the pig is 10 to 90 days old.
- When the cells to be transplanted are human-derived cells, heterotransplantation causes rejection. When the non-human animal into which cells are transplanted is the immunodeficient animal or the animal with induced immunological tolerance to human-derived cells as described above, rejection can be avoided. Otherwise, it is preferable to avoid rejection by administering an immunosuppressive agent (for example, ciclosporin) to the non-human animal.
- Although the secondary organ lacking a specific functional cell lacks the specific functional cell, the secondary organ has other functional cells and tissues, and thus, the secondary organ is presumed to have an environment favorable for differentiation into the specific functional cell. Therefore, when progenitor cells or pluripotent stem cells are transplanted into this organ, the cells are expected to differentiate into the specific functional cells without requiring a particular treatment. However, a substance such as an agent and a growth factor may be injected into the secondary organ to promote differentiation into the specific functional cell.
- The functional cells are collected from the secondary organ at an appropriate time after transplantation. The timing for collection can be decided as appropriate depending on the cell type, the type of the secondary organ, the type of the animal, and the like. When β cells are collected from the pancreas of a pig, the β cells are usually collected, without particular limitations, 1 to 12 months after transplantation.
- Although a method other than the method of the present invention, for example, a blastocyst complementation method can be used to produce a human-derived functional cell in a non-human animal, the inventive method is superior to a conventional method in the following respects.
- (a) In the blastocyst complementation method, human-derived cells are transplanted at an early stage of development such as a blastocyst stage. Such transplantation at an early stage of development leads to dilution of the human-derived cells. Specifically, some of the transplanted human-derived cells differentiate into functional cells but the majorities thereof differentiate into different cells other than the functional cells or disappear, which leads to a lower quantity of resulting human-derived functional cells. In contrast to this method, in the method of the present invention, human-derived cells are transplanted into an already differentiated organ. Therefore, it is expected that the majority of the transplanted cells differentiate into functional cells and abundant human-derived functional cells are obtained.
- (b) In the blastocyst complementation method, human-derived cells are transplanted into the blastocyst. The cells included in the blastocyst are undifferentiated cells and these cells differentiate into adult cells over time. The transplanted human-derived cells cannot become functional cells in the end unless the transplanted cells themselves differentiate at the same pace as the differentiation progress of such host cells. Therefore, it is presumed that there are many human-derived cells that cannot become functional cells because of relation to the differentiation progress of the host cells. In the method of the present invention, human-derived cells are transplanted into an already differentiated organ, and therefore, the above described problem associated with the differentiation progress of the host cells is presumed not to occur.
- (D) Secondary Organ
- The secondary organ of the present invention is a secondary organ developed by raising a newborn or a fetus of a non-human animal in which organ formation is inhibited, wherein the secondary organ lacks a specific functional cell.
- The type of the functional cell, the type of the secondary organ lacking a specific functional cell, and the type of the animal to be subjected to inhibition of organ formation may be similar to those described in the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.” The method for inhibiting organ formation and the method for raising a newborn or a fetus can also be performed in a similar manner to the above “Method for Developing Secondary Organ by Using Non-human Animal in which Organ Formation is Inhibited.”
- Hereinbelow, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
- The present inventors previously generated a chimeric pig that had a pancreas derived from a donor by injecting an embryo from a normal pig (donor embryo) into an embryo from a Pdx1-Hes1 gene-carrying and pig in which pancreas formation is inhibited (host embryo) and then allowing this to develop in the body of a surrogate parental pig (Matsunari et al., PNAS 110: 4557-4562 (2013)). A male of this chimeric pig can be naturally mated with a female wild type pig, thereby obtaining pancreas formation-inhibited newborns always at a certain ratio.
- The newborn piglet in which pancreas formation is inhibited to be used in this
- Example was obtained by natural mating with such a chimeric pig.
- A newborn piglet in which pancreas formation is inhibited (precisely, that has only rudimentary pancreatic tissue) by carrying a Pdx1-Hes1 gene lacks an endocrine cell (for example, a β cell producing insulin) and an exocrine cell. Consequently, the piglet dies about three days after birth due to extreme hyperglycemia and dyspepsia.
- Insulin and a digestive enzyme combination were administered as appropriate to such a newborn piglet in which pancreas formation is inhibited to bring the blood glucose level close to a normal level and induce individual growth and development of the pancreas.
- 1) Insulin Preparation:
- Levemir (Novo Nordisk) was administered at a dose of 0.2 to 0.3 IU/kg twice a day, or Tresiba (Novo Nordisk) was administered once a day.
- 2) Insulin Administration Method:
- Insulin was administered by subcutaneous injection or continuously administered with an insulin pump.
- 3) Digestive Enzyme Combination Agent:
- A daily dose of 150 mg to 750 mg of Berizym (SHIONOGI & CO., LTD.) was mixed with a milk substitute or solid (powdered) laboratory chow and given to the piglet. Berizym contains lipase, cellulase, biodiastase, and pancreatin.
- 4) Laboratory Chow and Feeding Method:
- From 0 to 7 days after birth, the piglet was fed with the milk substitute by a human or fed with milk by the mother pig. From 8 days after birth onward, the piglet was subjected to restricted feeding (the piglet is not allowed to eat ad libitum and is fed with a fixed daily amount of food) using a powdered milk substitute or powdered laboratory chow.
- 1) Controlled Blood Glucose Level and Growth:
- When a newborn piglet in which pancreas formation is inhibited was raised according to the method described in Example 2, the blood glucose level thereof was controlled to some extent and the individual grew as shown in
FIG. 2 . - 2) Blood Biochemical Parameters:
- Blood biochemical parameters for the pig in which pancreas formation is inhibited (
FIG. 3 ) indicate that insulin production remained abolished and glucagon production occured as the pig grew. Glucagon production was also confirmed by immunostaining of the developed pancreatic tissue (FIG. 4 ). In contrast, no insulin production was observed by immunostaining of the pancreatic tissue, either (FIG. 4 ). - 3) Development of Pancreas:
- Supported raising of the newborn piglet in which pancreas formation is inhibited led to development of the rudimentary pancreatic tissue (
FIGS. 5 and 6 ). Although the pancreatic tissue was about one tenth as big as a wild type pancreatic tissue (FIG. 7 ), amylase production was also observed (FIG. 8 ). - The pancreatic tissue developed by supported raising of the newborn piglet in which pancreas formation is inhibited lacks a β cell, which is a specific functional cell, but has other functional cells and tissue. Therefore, it is presumed that transplanting into this tissue a progenitor cell of the specific functional cell or a pluripotent stem cell whose differentiation was appropriately induced allows for establishment and growth of the specific functional cell.
- To verify this, autologous cells (fibroblasts) were injected into the pancreatic tissue of a 3.5-month-old pig in which pancreas formation is inhibited. Consequently, the autologous cells formed a colony (
FIG. 9 ). It is presumed that when the cell to be transplanted is a progenitor cell of a β cell or a pluripotent stem cell, β cells can be formed and grown by utilizing the environment of the pancreatic tissue. Specifically, it is believed that human pancreatic functional cells (for example, β cells) can be developed by allowing human pluripotent stem cells to establish themselves in the environment within the developing pancreatic tissue of the pig in which pancreas formation is inhibited. - 1) Diabetic Retinopathy
- A newborn piglet in which pancreas formation is inhibited was raised according to the method described in Example 2. The immunohistochemically stained image of the retina was observed after 80 days of raising and a pathological image characteristic of diabetic retinopathy was identified (
FIG. 10 ). On the other hand, the retina of a wild type pig was healthy after raising for the same length of time (FIG. 10 ). - 2) Cataract
- A newborn piglet in which pancreas formation is inhibited was raised according to the method described in Example 2. The eye was observed after 39 days of raising and development of cataract was identified (
FIG. 11 ). On the other hand, the eye of a wild type pig was healthy after raising for the same length of time (FIG. 11 ). - All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.
- The present invention relates to a non-human animal that has a secondary organ lacking a specific functional cell, and thus, is applicable to the field of industry that handles such an animal.
Claims (5)
1-18. (canceled)
19. A method for establishment and growth of a progenitor cell of a specific functional cell or a pluripotent stem cell, or a functional cell derived therefrom, comprising transplanting the progenitor cell or the pluripotent stem cell into an organ-like tissue, wherein the organ-like tissue is formed by a newborn or a fetus of a genetically modified pig and lacks a functional cell derived from the pig.
20. The method according to claim 19 , wherein the progenitor cell of the functional cell or the pluripotent stem cell is a human-derived cell.
21. A material in which a progenitor cell of a specific functional cell or a pluripotent stem cell, or a functional cell derived therefrom is established and grown, the material lacking a functional cell derived from the pig and comprising organ-like tissue formed by a newborn or a fetus of a genetically modified pig, wherein the progenitor cell or the pluripotent stem cell is transplanted into the organ-like tissue.
22. The material according to claim 21 , wherein the progenitor cell of the functional cell or the pluripotent stem cell is a human-derived cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/495,087 US20220022433A1 (en) | 2017-09-19 | 2021-10-06 | Method for developing organ that lacks specific functional cell |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017178552 | 2017-09-19 | ||
JP2017-178552 | 2017-09-19 | ||
PCT/JP2018/034390 WO2019059158A1 (en) | 2017-09-19 | 2018-09-18 | Method for developing organ lacking specific functional cell |
US202016638440A | 2020-02-11 | 2020-02-11 | |
US17/495,087 US20220022433A1 (en) | 2017-09-19 | 2021-10-06 | Method for developing organ that lacks specific functional cell |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/034390 Continuation WO2019059158A1 (en) | 2017-09-19 | 2018-09-18 | Method for developing organ lacking specific functional cell |
US16/638,440 Continuation US11172657B2 (en) | 2017-09-19 | 2018-09-18 | Method for developing organ that lacks specific functional cell |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220022433A1 true US20220022433A1 (en) | 2022-01-27 |
Family
ID=65655803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/638,440 Active US11172657B2 (en) | 2017-09-19 | 2018-09-18 | Method for developing organ that lacks specific functional cell |
US17/495,087 Pending US20220022433A1 (en) | 2017-09-19 | 2021-10-06 | Method for developing organ that lacks specific functional cell |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/638,440 Active US11172657B2 (en) | 2017-09-19 | 2018-09-18 | Method for developing organ that lacks specific functional cell |
Country Status (6)
Country | Link |
---|---|
US (2) | US11172657B2 (en) |
EP (1) | EP3685661A4 (en) |
JP (2) | JP6479246B1 (en) |
SG (1) | SG11202002118XA (en) |
TW (1) | TW201920655A (en) |
WO (1) | WO2019059158A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090202977A1 (en) * | 2005-08-26 | 2009-08-13 | Regents Of The University Of Minnesota | Decellularization and recellularization of organs and tissues |
JP2014121329A (en) * | 2007-02-22 | 2014-07-03 | Univ Of Tokyo | Organ regeneration method using BLASTOCYSTCOMPLEMENTATION |
US20200137991A1 (en) * | 2017-01-25 | 2020-05-07 | The University Of Tokyo | Finding and treatment of inflammation after birth in chimeric animal |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106368A0 (en) * | 1992-07-24 | 1993-11-15 | Univ Pennsylvania | Non-native liver generation in an animal with impaired native liver function,by cell implantation |
US6071697A (en) | 1992-08-03 | 2000-06-06 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Method for testing the differentiation status in pancreatic cells of a mammal |
DE69431107T2 (en) * | 1993-05-24 | 2003-03-27 | Ximerex Inc | THE GENERATION OF TOLERANCE AGAINST FOREIGN TRANSPLANTS BY TOLEROGENESIS WITH THE HELP OF REPLACEMENT LIVES |
DK0958357T3 (en) * | 1996-12-31 | 2006-02-20 | Max Planck Gesellschaft | Hitherto unknown method for testing the differentiation status of mammalian pancreatic cells |
RU2236127C2 (en) * | 1998-03-30 | 2004-09-20 | Рисерч Дивелопмент Фаундейшн | Method for preparing transgenic mouse no comprising functional receptor-1 corticotropin releasing-factor, method for identifying agonist or antagonist of corticotropin releasing-factor, urocortin or ligand of corticotropin releasing-factor and method for screening compounds that are analogs or agonists of corticosterone or corticotropin using such mouse |
RU2268065C2 (en) * | 1999-03-17 | 2006-01-20 | Зольвай Фармасьютиклз Гмбх | Drug for treating diabetes cases |
US6525242B1 (en) * | 1999-11-02 | 2003-02-25 | The University Of Connecticut | Propagation of human hepatocytes in non-human mammals |
US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
WO2009104794A1 (en) | 2008-02-22 | 2009-08-27 | 国立大学法人 東京大学 | Method for producing founder animal for reproducing animals having lethal phenotype caused by gene modification |
GB2475656B (en) | 2008-08-22 | 2013-04-24 | Univ Tokyo | Organ regeneration method utilizing ips cell and blastocyst complementation |
EP2464219B1 (en) | 2009-08-14 | 2019-10-23 | Revivicor, Inc. | Multi-transgenic pigs for diabetes treatment |
US20110218191A1 (en) | 2010-03-03 | 2011-09-08 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long term-treatment of kidney disorders in cats |
JP5841322B2 (en) | 2010-04-22 | 2016-01-13 | オレゴン ヘルス アンド サイエンス ユニバーシティ | Fumaryl acetoacetate hydrolase (FAH) deficient pig and use thereof |
JP6530342B2 (en) | 2016-03-30 | 2019-06-12 | 株式会社日立製作所 | Elevator equipment |
-
2018
- 2018-09-18 US US16/638,440 patent/US11172657B2/en active Active
- 2018-09-18 WO PCT/JP2018/034390 patent/WO2019059158A1/en unknown
- 2018-09-18 SG SG11202002118XA patent/SG11202002118XA/en unknown
- 2018-09-18 EP EP18858805.7A patent/EP3685661A4/en active Pending
- 2018-09-18 JP JP2018173749A patent/JP6479246B1/en active Active
- 2018-09-19 TW TW107132926A patent/TW201920655A/en unknown
-
2019
- 2019-02-05 JP JP2019018434A patent/JP2019062929A/en active Pending
-
2021
- 2021-10-06 US US17/495,087 patent/US20220022433A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090202977A1 (en) * | 2005-08-26 | 2009-08-13 | Regents Of The University Of Minnesota | Decellularization and recellularization of organs and tissues |
JP2014121329A (en) * | 2007-02-22 | 2014-07-03 | Univ Of Tokyo | Organ regeneration method using BLASTOCYSTCOMPLEMENTATION |
US20200137991A1 (en) * | 2017-01-25 | 2020-05-07 | The University Of Tokyo | Finding and treatment of inflammation after birth in chimeric animal |
Non-Patent Citations (2)
Title |
---|
Baulier et al. Stem Cell Translation Medicine 2014:809-820 (Year: 2014) * |
Fujiki et al. Transplantation 75(2):916-922, 2003 (Year: 2003) * |
Also Published As
Publication number | Publication date |
---|---|
TW201920655A (en) | 2019-06-01 |
JP2019054790A (en) | 2019-04-11 |
EP3685661A4 (en) | 2021-05-19 |
SG11202002118XA (en) | 2020-04-29 |
US20200165633A1 (en) | 2020-05-28 |
JP6479246B1 (en) | 2019-03-06 |
WO2019059158A1 (en) | 2019-03-28 |
US11172657B2 (en) | 2021-11-16 |
JP2019062929A (en) | 2019-04-25 |
EP3685661A1 (en) | 2020-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cornelius et al. | In vitro-generation of islets in long-term cultures of pluripotent stem cells from adult mouse pancreas | |
US6001647A (en) | In vitro growth of functional islets of Langerhans and in vivo uses thereof | |
JP3621106B2 (en) | In vitro culture of functional islets of Langerhans and its in vivo use | |
CN103865871A (en) | Selective cell therapy for the treatment of renal failure | |
US6114599A (en) | Recombinant β-cell and uses thereof | |
AU739771B2 (en) | In vitro growth of functional islets of langerhans and in vivo uses thereof | |
Tuch et al. | Histologic differentiation of human fetal pancreatic explants transplanted into nude mice | |
Zhu et al. | Optimal pig donor selection in islet xenotransplantation: current status and future perspectives | |
Fukuda et al. | The intraperitoneal space is more favorable than the subcutaneous one for transplanting alginate fiber containing iPS-derived islet-like cells | |
Luca et al. | Accelerated functional maturation of isolated neonatal porcine cell clusters: in vitro and in vivo results in NOD mice | |
US20220022433A1 (en) | Method for developing organ that lacks specific functional cell | |
Kobayashi et al. | Organ fabrication using pigs as an in vivo bioreactor | |
US7384630B2 (en) | Chimeric pancreas | |
US9089550B2 (en) | Combined islet transplantation using pancreatic islets and adipose tissue derived stem cells | |
JP2001333770A (en) | Method for in vitro formation of pancreas of vertebrate animal | |
Nagaya et al. | Feasibility of large experimental animal models in testing novel therapeutic strategies for diabetes | |
KR100569163B1 (en) | Method for Producing Avian Chimera Using Spermatogonial Cells and Avian Chimera | |
US20090214482A1 (en) | Transgenic Mammals Expressing Human Preproinsulin | |
Hammerman | Engraftment of insulin-producing cells from porcine islets in non-immune-suppressed rats or nonhuman primates transplanted previously with embryonic pig pancreas | |
Pursel et al. | Gene transfer for enhanced growth of livestock | |
FLORIDA | In vitro growth of functional islets of Langerhans and in vivo uses thereof | |
CN103911393A (en) | Construction and application of mammary specific expression vector for human transferrin | |
CN102379756A (en) | Method for transforming organ of donor into organ consisting of cell of receptor | |
Susa | Methodology for the Study of Metabolism: Physiologic Modeling in Animals | |
BOLT | VERNON G. PURSEL, CAIRD E. REXROAD, JR., AND DOUGLAS J. BOLT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |